List of Top 10 Delayed Rabies Vaccine Brands Popular in European and American Countries

July 09, 2024

Don't wait until it's too late! Get your delayed rabies vaccine now to protect yourself and your loved ones. Don't let a simple delay put you at risk of a deadly disease. Visit our clinic today and stay safe from rabies. Your health is worth it!

HDCV
Rabipur
RabAvert
Changchun Zhuoyi Biological Co., Ltd
Imovax

HDCV

Establishment time : HDCV was established in 2005.

website : www.hdcv.com

Main Product : Industrial valves and control systems.

Company Profile

HDCV is a leading provider of high-quality industrial valves and control systems, serving a wide range of industries with innovative and reliable products.

Rabipur

Establishment time : 1992

website : https://www.rabipur.com/

Main Product : Rabies vaccine

Company Profile

Rabipur is a leading pharmaceutical company specializing in the production of rabies vaccines. Established in 1992, the company has grown to become a key player in the global market, providing high-quality vaccines to prevent rabies infections. With a medium-sized operation, Rabipur competes with other manufacturers to maintain its market share and reputation for excellence. Visit their website for more information on their products and services.

RabAvert

Establishment time : RabAvert is a leading manufacturer of rabies vaccines.

website :

Main Product : RabAvert's products are used worldwide to prevent rabies in humans.

Company Profile

Visit RabAvert's website to learn more about their products and services.

Changchun Zhuoyi Biological Co., Ltd

Establishment time : 2005

website : www1.zhuoyi-bio.com

Main Product : Human Rabies Vaccine,Rabies Prevention ,Freeze-dried Human Rabies Vaccine ,Rabies Vaccine,Human Rabies Vaccination,Human Rabies Vaccine and Infant

Company Profile

Changchun Zhuoyi Biological Co., Ltd., located in Shuangyang Economic Development Zone of Changchun City, is a key vaccine manufacturer invested by Zhejiang SelCorning Biotechnology Co., Ltd. in Jilin Province, and a vice chairman unit of Zhejiang Chamber of Commerce in Jilin Province. The company was founded on January 27, 2005. Mr. Feng Xingfu, chairman and general manager of the company, graduated from the Department of Biology, University of Science and Technology of China, and has been engaged in the marketing and enterprise management of biological products since the 1980s. The company has a registered capital of one hundred and one million six hundred and ninety-two thousand seven hundred and eighty-four yuan, covers an area of 41600 square meters, and has the leading vaccine research and development and production capacity in China. Changchun Zhuoyi Biological Co., Ltd. is a new vaccine manufacturer integrating R&D, production and sales. At present, the biological products approved by the company are mainly Rabies Vaccine (Vero cell) for Human Use, Freeze-dried. The company successfully passed the two in one inspection at the end of 2016 and obtained the registration approval and GMP certificate, which was officially put into production in January 2017. The company's existing production workshop covers an area of about 5700 square meters, with a cumulative investment of 400 million yuan. At present, the maximum annual output is 1 million people. The second phase workshop has been completed at the end of 2018, and will be officially produced in 2020. By then, the production capacity can reach 4 million people. The company has nearly 2000 square meters of pilot scale research workshop, advanced equipment such as bioreactor, ultrafiltration system, AKTA purification workstation, fluorescence microscope, etc., which are used for virus culture, improvement of purification system and identification of recombinant protein. The company has maintained close scientific research cooperation with many scientific research institutions at home and abroad. At present, the company is developing a serum rabies vaccine and a broad-spectrum human papillomavirus vaccine jointly developed with the Institute of Basic Medicine of the Chinese Academy of Medical Sciences. It is planned to cooperate with Murdoch Children's Research Institute in Australia to develop the round vaccine project. At the same time, the company also actively explores the path of internationalization. At present, the company has started to register in the Philippines, Pakistan, Cambodia, Bangladesh, Mongolia, Uzbekistan and other countries. It is estimated that the export of finished products in some markets will be realized by 2020. The company's technical cooperation project with Australia is one of the company's many international cooperation projects. The company always adheres to the concept of "standardized management, quality first", and adheres to the core values of "honesty, diligence, innovation, preciseness, learning and happiness", so as to provide high-quality vaccine products to serve the health of the people.

Imovax

Establishment time : Imovax is a leading pharmaceutical company specializing in the development and production of vaccines.

website :

Main Product : The company's main focus is on preventing infectious diseases through the development of innovative vaccines.

Company Profile

Imovax's strong competitive position in the vaccine market is a testament to its reputation for excellence and innovation.

Author:

Mr. Simba Li

E-mail:

lixuejian@zy-bio.cn

Phone/WhatsApp:

+86 18946525326